Proactive Investors - Run By Investors For Investors

Cellmid banks research and development tax incentive

Cellmid’s consumer health segment generates revenue by selling anti-ageing functional cosmetics and consumer health products.
cosmetics
The company is closing in on profitability.

Cellmid Limited (ASX:CDY) has received $808,000 from the Australian Taxation Office under the Research and Development Tax Incentive Scheme for the 2018 financial year.

The tax credit relates to research and development expenditure incurred by Cellmid in relation to its midkine (MK) and FGF5 inhibitor programs.

Cellmid’s évolis® hair growth product range was developed using FGF5 related intellectual property.

The company aims to follow in the footsteps of FGF5 by commercialising its MK portfolio through various deals and partnerships.

READ: Cellmid driving towards profitability with anti-ageing product range

Cellmid’s consumer health segment generates revenue by selling anti-ageing functional cosmetics and consumer health products for hair, face and wellbeing.

The segment generated $5.64 million in revenue in FY2018 and as Cellmid expands its product range and selling markets, it is closing in on profitability.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use